<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Capital Trust</title>
	<atom:link href="http://www.stockbloghub.com/tag/capital-trust/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Tue, 22 May 2012 18:53:06 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(BDX) Becton, Dickinson and Co Receives FDA Clearance</title>
		<link>http://www.stockbloghub.com/2009/12/09/bdx-becton-dickinson-and-co-receives-fda-clearance/22376</link>
		<comments>http://www.stockbloghub.com/2009/12/09/bdx-becton-dickinson-and-co-receives-fda-clearance/22376#comments</comments>
		<pubDate>Wed, 09 Dec 2009 23:23:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International Inc]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[Capital Trust]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22376</guid>
		<description><![CDATA[Becton, Dickinson and Co. (BDX) recently announced that BD Diagnostics, a segment of BDX, has received U.S. Food and Drug Administration (FDA) clearance to utilize its BD ProbeTec Chlamydia trachomatis (CT) Qx and BD ProbeTec Neisseria gonorrhoeae (GC) Qx Amplified DNA Assays with samples collected from women&#8217;s routine liquid-based Pap testing for cervical cancer screening. The BD ProbeTec Qx Amplified DNA Assays are the first to receive FDA clearance for gynecological specimens collected and transported for Pap testing in cervical cancer. Pap testing is one of the two leading types of liquid-based cytology (LBC) preservative media on the market today. Pap Testing uses detachable-head collection devices that ensure that 100% of collected cells are sent to the laboratory for analysis. The ability to test for chlamydia and gonorrhea while screening ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/09/bdx-becton-dickinson-and-co-receives-fda-clearance/22376/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CT) Avoid Regional Domestic Banks &#8211; Zacks Industry Rank Analysis</title>
		<link>http://www.stockbloghub.com/2009/11/28/ct-avoid-regional-domestic-banks-zacks-industry-rank-analysis/21414</link>
		<comments>http://www.stockbloghub.com/2009/11/28/ct-avoid-regional-domestic-banks-zacks-industry-rank-analysis/21414#comments</comments>
		<pubDate>Sun, 29 Nov 2009 03:46:01 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[Property Management]]></category>
		<category><![CDATA[BAC]]></category>
		<category><![CDATA[Banco Bradesco S.A.]]></category>
		<category><![CDATA[Banco Santander-Chile]]></category>
		<category><![CDATA[Bank of America Corporation]]></category>
		<category><![CDATA[BBD]]></category>
		<category><![CDATA[Capital Trust]]></category>
		<category><![CDATA[Credit Suisse Group]]></category>
		<category><![CDATA[CS]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[DB]]></category>
		<category><![CDATA[Deutsche Bank AG]]></category>
		<category><![CDATA[Fannie Mae]]></category>
		<category><![CDATA[FNM]]></category>
		<category><![CDATA[FRE]]></category>
		<category><![CDATA[Freddie Mac]]></category>
		<category><![CDATA[Glimcher Realty Trust]]></category>
		<category><![CDATA[GRT]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[PEBO]]></category>
		<category><![CDATA[Peoples Bancorp Inc]]></category>
		<category><![CDATA[Privatebancorp Inc]]></category>
		<category><![CDATA[PVTB]]></category>
		<category><![CDATA[Ramco-Gershenson Properties Trust]]></category>
		<category><![CDATA[RPT]]></category>
		<category><![CDATA[SAN]]></category>
		<category><![CDATA[SBIB]]></category>
		<category><![CDATA[Sterling Bancshares Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21414</guid>
		<description><![CDATA[Industry Rank Analysis 11-25-09 Commercial real estate is in big trouble, with rising vacancy rates leading to lower effective rents. On top of that, the Cap rate, which is sort of like the P/E ratio for stocks (or to be more precise, like the E/P or earnings yield for stocks), has been rising, meaning that investors are willing to pay less for each dollar of operating earnings. Moody’s recently estimated that commercial real estate values are now 43% below peak levels. This has weighed heavily on the real estate-related industries, and the Zacks Industry Ranks reflect those troubles. Out of 206 industries that we follow, Real Estate Operations now rank 180, with an average Zacks Rank of its constituents of 3.31. The ranks range from 1-5; Zacks #1 Rank stocks ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/28/ct-avoid-regional-domestic-banks-zacks-industry-rank-analysis/21414/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

